RxDoctor Payments Data

Paula Montana de la Cadena, MD

Cardiovascular Disease · Miami, FLNPI 1548435019

Payments from drug & device makers

$11,871in general payments, 2019–2025

Across 252 payments — averaging $47.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$3K
  • Medtronic$1K
  • Novo Nordisk$835
  • AstraZeneca$757
  • Johnson & Johnson$552
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$11,77199%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,871 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$106,431
Medicare patients
686
Services billed
1,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban259$341,261
JardianceEmpagliflozin238$326,515
EntrestoSacubitril/Valsartan177$241,707
FarxigaDapagliflozin Propanediol138$170,596
Repatha SureclickEvolocumab110$126,966
XareltoRivaroxaban84$104,117
OzempicSemaglutide80$91,037
VascepaIcosapent Ethyl89$57,943
Icosapent Ethyl29$13,093
Metoprolol Succinate518$6,960
Atorvastatin Calcium727$6,684
Rosuvastatin Calcium459$6,342
Ezetimibe240$5,953
Valsartan149$4,091
Bumetanide149$3,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$479$341,261259 claims
Boehringer IngelheimJardiance$80$326,515238 claims
NovartisEntresto$300$241,707177 claims
AstraZenecaFarxiga$757$170,596138 claims
Johnson & JohnsonXarelto$552$104,11784 claims
Novo NordiskOzempic$835$91,03780 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →